Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging

Developmental Brain Research

Volumn 101, Issue 1-2, 1997, Pages 93-105

  Court, J A ^a   Lloyd, S ^a   Johnson, M ^a   Griffiths, M ^a   Birdsall, N J M ^b   Piggott, M A ^a   Oakley, A E ^a   Ince, P G ^a   Perry, E K ^a   Perry, R H ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Bungarotoxin receptor; Aging; Development; Entorhinal cortex; Hippocampus; Human brain; Muscarinic receptor; Nicotinic receptor

Indexed keywords

MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR;

ADOLESCENT; ADULT; AGED; AGING; ARTICLE; BINDING AFFINITY; BRAIN DEVELOPMENT; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INFANT; MALE; NEWBORN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SUBICULUM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; AUTORADIOGRAPHY; BUNGAROTOXINS; CHILD; CHILD, PRESCHOOL; FEMALE; HIPPOCAMPUS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; N-METHYLSCOPOLAMINE; PARASYMPATHOLYTICS; PREGNANCY; RECEPTORS, MUSCARINIC; RECEPTORS, NICOTINIC; SCOPOLAMINE DERIVATIVES;

EID: 0030753358     PISSN: 01653806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-3806(97)00052-7     Document Type: Article

References (124)

1. Abdallah E.A.M., Pou W.S., El-Fakahany E.E. Aging does not alter muscarinic receptor-mediated inhibition of cyclic AMP formation in the striatum and hippocampus. Brain Res. 534:1990;234-236.
2. Aguilar J.S., Lunt G.G. Muscarinic receptor sites in human foetal brain. Neurochem. Int. 7:1985;509-514.
3. Amenta F., Liu A., Zeng Y.C., Zaccheo D. Muscarinic cholinergic receptors in the hippocampus of aged rats: influence of choline alphoscerate treatment. Mech. Aging Dev. 76:1994;49-64.
4. Araujo D.M., Lapchak P.A., Meaney M.J., Collier B., Quirion R. Effects of aging on nicotinic and muscarinic autoreceptor function in the rat brain: relationship to presynaptic cholinergic markers and binding sites. J. Neurosci. 10:1990;3069-3078.
5. Aronstam R., Kellogg C., Abood L. Development of muscarinic cholinergic receptors in inbred strains of mice: identification of receptor heterogeneity and relation to audiogenic seizure susceptibility. Brain Res. 162:1979;231-241.
6. Arriagada P.V., Marzloff K., Hyman B.T. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology. 42:1992;1681-1688.
7. Aubert I., Araujo D.M., Cécyre D., Robitaille Y., Gauthier S., Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's disease and Parkinson's disease. J. Neurochem. 58:1992;529-541.
8. Aubert I., Rowe W., Meaney M.J., Gauthier S., Quirion R. Cholinergic markers in aged cognitively impaired Long-Evans rats. Neuroscience. 67:1995;277-292.
9. Bar-Peled O., Israeli M., Ben-Hur H., Hoskins I., Groner Y., Biegon A. Developmental pattern of muscarinic receptors in normal and Down's syndrome fetal brain - an autoradiographic study. Neurosci. Lett. 133:1991;154-158.
10. Barrantes G.E., Rogers A.T., Lindstrom J., Wonnacott S. α-Bungarotoxin binding sites in rat hippocampal and cortical cultures: initial characterisation, colocalisation with α7 subunits and up-regulation by chronic nicotine treatment. Brain Res. 672:1995;228-236.
11. 3H]nicotine binding sites in human brain. J. Neurochem. 50:1988;1243-1247.
12. Biegon A., Hanau M., Greenberger V., Segal M. Aging and brain cholinergic muscarinic receptor subtypes: An autoradiographic study in the rat. Neurobiol. Aging. 10:1989;305-310.
13. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82:1991;239-259.
14. Brann M.R., Ellis J., Jørgensen H., Hill-Eubanks D., Jones S.V.P. Muscarinic acetylcholine receptor subtypes: localization and structure/function. Prog. Brain Res. 98:1993;121-127.
15. Broide R.S., O'Connor L.T., Smith M.A., Smith J.A.M., Leslie F.M. Developmental expression of α7 neuronal nicotinic receptor messenger RNA in rat sensory cortex and thalamus. Neuroscience. 67:1995;83-94.
16. Brooksbank B.W.L., Martinez M., Atkinson D.J., Balazs R. Biochemical development of the human brain: 1. Some parameters of the cholinergic system. Dev. Neurosci. 1:1978;267-284.
17. Buckley N., Bonner T., Buckley C., Brann M. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol. Pharmacol. 35:1989;469-476.
18. Butler N.R., Goldstein H. Smoking in pregnancy and subsequent child development. Br. Med. J. 4:1973;573-574.
19. 3H](-)nicotine binding sites in fetal human brain. Brain Res. 475:1988;1-7.
20. Candura S.M., Tonini M., Baiardi P., Manzo L., Costa L.G. Heterogeneity of cholinergic muscarinic receptors coupled to phosphoinositide metabolism in immature rat brain. Dev. Brain Res. 86:1995;134-142.
21. Chouinard M., Gallagher M., Yasuda R., Wolfe B., McKinney M. Hippocampal muscarinic receptor function in spatial learning-impaired aged rats. Neurobiol. Aging. 16:1995;955-963.
22. Clarke P.B.S. The fall and rise of neuronal α-bungarotoxin binding proteins. Trends Pharmacol. Sci. 13:1992;407-413.
23. 125I]-α-bungarotoxin. J. Neurosci. 5:1985;1307-1315.
24. Consolo S., Wang J., Fiorentini F., Vezzani A., Ladinsky H. In vivo and in vitro studies on the regulation of cholinergic neurotransmission in striatum, hippocampus and cortex of aged rats. Brain Res. 374:1986;212-218.
25. Costa, L.G., Muscarinic receptors and the developing nervous system, in: I.S. Zagon and P.J. McLaughlin (Eds.), Receptors in the Developing Nervous System, vol. 2: Neurotransmitters, Chapman and Hall, London, 1993, pp. 21-42.
26. Court, J.A. and Perry, E.K., Distribution of nicotinic receptors in the CNS, in: T.W. Stone (Ed.), CNS Neurotransmitters and Neuromodulators: Acetylcholine, CRC Press, Boca Raton, 1995, pp. 85-104.
27. Court J.A., Perry E.K., Johnson M., Piggott M.A., Kerwin J.M., Perry R.H., Ince P.G. Regional patterns of cholinergic and glutamate activity in the developing and aging human brain. Dev. Brain Res. 74:1993;73-82.
28. Court J.A., Perry E.K., Spurden D., Griffiths M., Kerwin J.M., Morris C.M., Johnson M., Oakley A.E., Birdsall N.J.M., Clementi F., Perry R.H. The role of the cholinergic system in the development of the human cerebellum. Dev. Brain Res. 90:1995;159-167.
29. Court J.A., Piggott M.A., Perry E.K., Barlow R.B., Perry R.H. Age associated decline in high affinity nicotine binding in human brain frontal cortex does not correlate with the changes in choline acetyltransferase activity. Neurosci. Res. Comm. 10:1992;125-133.
30. Davies P., Feisullin S. Postmortem stability of α-bungarotoxin binding sites in mouse and human brain. Brain Res. 216:1981;449-454.
31. 2+/calmodulin-dependent kinase pathway. J. Neurosci. 15:1995;7966-7978.
32. Decker M.W. The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system. Brain Res. Rev. 12:1987;423-438.
33. Dewey S., Volkow N., Logan J., MacGregor R., Fowler J., Schlyer D., Bendriem B. Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET). J. Neurosci. Res. 27:1996;569-575.
34. Didier M., Berman S.A., Lindstrom J., Bursztajn S. Characterization of nicotinic acetylcholine receptors expressed in primary cultures of cerebellar granule cells. Mol. Brain Res. 30:1995;17-28.
35. Didier M., Bix G., Berman S.A., Bursztajn S. Expression of the α4 neuronal nicotinic acetylcholine receptor subunit in the developing mouse hippocampus. Int. J. Dev. Neurosci. 13:1995;705-713.
36. Dravid A. Deficits in cholinergic enzymes and muscarinic receptors in the hippocampus and striatum of senescent rats: Effect of chronic hydergine treatment. Arch. Int. Pharmacodyn. Ther. 264:1983;195-202.
37. Eriksson M., Larsson G., Zetterstrom R. Abuse of alcohol, drugs and tobacco during pregnancy: consequences for the child. Paediatrician. 8:1979;228-242.
38. Fiedler E.P., Marks M.J., Collins A.C. Postnatal development of two nicotinic cholinergic receptors in seven mouse brain regions. Int. J. Dev. Neurosci. 8:1990;533-540.
39. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4β2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol. 41:1992;31-37.
40. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J. Neurochem. 47:1986;1948-1954.
41. Gall C.M. Regulation of brain neurotrophin expression by physiological activity. Trend. Pharmacol. Sci. 13:1992;401-403.
42. Gilad G., Rabey J., Shenkman L., Gilad V. Selective influence of rat genotype on age-related regional changes in forebrain muscarinic binding. Neurobiol. Aging. 8:1987;517-520.
43. Greenwood A., Powers R., Jope R. Phosphoinositide hydrolysis, Galphaq, phospholipase C, and protien kinase C in post mortem human brain: Effects of post mortem interval, subject age, and Alzheimer's disease. Neuroscience. 69:1995;125-138.
44. Haba K., Ogawa N., Kawata M., Mori A. A method for parallel determination of choline acetyltransferase and muscarinic cholinergic receptors: application in aged-rat brain. Neurochem. Res. 13:1988;951-955.
45. Heacock A., Fisher S., Agranoff B. Enhanced coupling of neonatal muscarinic receptors in rat brain to phosphoinositide turnover. J. Neurochem. 48:1987;1904-1911.
46. Ince P., Irving D., MacArthur F., Perry R.H. Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: Comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type, Parkinson's disease and non-demented elderly controls. J. Neurol. Sci. 106:1991;142-152.
47. Johnson M., Perry R.H., Piggott M.A., Court J.A., Spurden D., Lloyd S., Ince P.G., Perry E.K. Glutamate receptor binding in the human hippocampus and adjacent cortex during development and aging. Neurobiol. Aging. 17:1996;639-651.
48. Jonsson G., Hallman H. Effects of neonatal nicotine administration on the postnatal development of central noradrenaline neurons. Act. Physiol. Scand. 479(Suppl.):1980;25-26.
49. Kadar T., Silbermann M., Weissman B., Levy A. Age-related changes in the cholinergic components within the central nervous system. II. Working memory impairment and its relation to hippocampal muscarinic receptors Mech. Aging Dev. 55:1990;139-149.
50. 3H]nicotine binding in the human brainstem. Neuroscience. 55:1993;1127-1138.
51. 3H]nitrendipine to cerebral cortical and hippocampal membranes of senescence accelerated mouse. Neurosci. Lett. 106:1989;334-338.
52. Kubanis P., Zornetzer S., Freund G. Memory and postsynaptic cholinergic receptors in aging mice. Pharmacol. Biochem. Behav. 17:1982;313-322.
53. Kumar A., Schliebs R. Postnatal laminar development of cholinergic receptors, protein kinase C and dihydropyridine-sensitive calcium antagonist binding in rat visual cortex. Effect of visual deprivation. Int. J. Dev. Neurosci. 10:1992;491-504.
54. 11C]tropanyl benzilate. J. Cereb. Blood Flow Metab. 16:1996;303-310.
55. Lipton S.A., Kater S.B. Neurotransmitter regulation of neuronal outgrowth, plasticity and survival. Trends Neurol. Sci. 12:1989;265-270.
56. Longo L.D. The biological effects of carbon monoxide on the pregnant woman, fetus and newborn infant. Am. J. Obstet. Gyn. 129:1977;69-103.
57. Mash D.C., Flynn D.D., Potter L.T. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science. 228:1985;1115-1117.
58. McFarland B.J., Seidler F.J., Slotkin T.A. Inhibition of DNA synthesis in neonatal rat brain regions caused by acute nicotine administration. Dev. Brain Res. 58:1991;223-229.
59. McGehee D.S., Heath M.J.S., Gelber S., Devay P., Role L.W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 269:1995;1692-1696.
60. McGehee D.S., Role L.W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu. Rev. Physiol. 57:1995;521-546.
61. Michalek H., Fortuna S., Pintor A. Age-related differences in brain choline acetyltransferase, cholinesterases and muscarinic receptor sites in two strains of rats. Neurobiol. Aging. 10:1989;143-148.
62. Michalek H., Pintor A., Fortuna S. Responsiveness of brain muscarinic acetylcholine receptors in aged rats. Ann. Ist. Sup. San. 26:1990;61-68.
63. Morin A., Wasterlain C. Aging and rat brain muscarinic receptors as measured by quinuclidinyl benzilate binding. Neurochem. Res. 5:1980;301-308.
64. Mundy W., Tandon P., Ali S., Tilson H. Age-related changes in receptor mediated phosphoinositide hydrolysis in various regions of rat brain. Life Sci. 49:1991;PL97-PL102.
65. 3H]nicotine binding sites in rat brain regions: an autoradiographic study. Dev. Brain Res. 68:1992;163-174.
66. Nakayama H., Nakashima T., Kurogochi Y. α4 is a major acetylcholine binding subunit of cholinergic ligand affinity-purified nicotinic acetylcholine receptor from rat brains. Neurosci. Lett. 121:1991;122-124.
67. Narang N. In situ determination of M1 and M2 muscarinic receptor binding sites and mRNAs in young and old rat brains. Mech. Aging Dev. 78:1995;221-239.
68. Narang N., Joseph J., Ayyagari P., Gerber M., Crews F. Age-related loss of cholinergic-muscarinic coupling to PLC: Comparison with changes in brain regional PLC subtypes mRNA distribution. Brain Res. 708:1996;143-152.
69. Navarro H.A., Seidler F.J., Schwartz R.D., Baker F.E., Dobbins S.S., Slotkin T.A. Prenatal exposure to nicotine impairs nervous system development at a dose which does not affect viability or growth. Brain Res. Bull. 23:1989;187-192.
70. Nicholl, J. and O'Cathain, A., Antenatal smoking, passive smoking and the Sudden Infant Death Syndrome. In D. Poswillo and E. Alberman (Eds.), Effects of Smoking on the Fetus, Neonate and Child, Oxford University Press, Oxford, 1992, pp. 138-149.
71. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cereb. Brain Metab. Rev. 4:1992;303-328.
72. Nordberg A. Human nicotinic receptors - their role in aging and dementia. Neurochem. Int. 25:1994;93-97.
73. Nordberg, A. and Winblad, B., Brain nicotinic and muscarinic receptors in normal aging and dementia, in: A. Fisher and I. Hainin (Eds.), Alzheimer's and Parkinson's Disease - Strategies for Research and Development, vol. 29, Plenum Press, New York, 1986, pp. 95-108.
74. Nordberg A., Zhang X., Fredriksson A., Eriksson P. Neonatal nicotine exposure induces permanent changes in brain nicotinic receptors and behaviour in adult mice. Dev. Brain Res. 63:1991;201-207.
75. Ogawa N., Asanuma M., Kondo Y., Nishibayashi S., Mori A. Reduced choline acetyltransferase activity and muscarinic M1 receptor levels in aged Fischer 344 rat brains did not parallel their respective mRNA levels. Brain Res. 658:1994;87-92.
76. Parent A., Rowe W., Meaney M.J., Quirion R. Increased production of inositol phosphates and diacylglycerol in aged cognitively impaired rats after stimulation of muscarinic, metabotropic-glutamate and endothelin receptors. J. Pharmacol. Exp. Ther. 272:1995;1110-1116.
77. Pedigo N., Minor L., Krumrei T. Cholinergic drug effects and brain muscarinic receptor binding in aged rats. Neurobiol. Aging. 5:1984;227-233.
78. 3H]nicotine binding in human cortex: Relative abundance in subicular complex. J. Chem. Neuroanat. 5:1992;399-405.
79. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., Perry R.H. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience. 64:1995;385-395.
80. Perry E.K., Perry R.H., Smith C.J., Dick D.J., Candy J.M., Edwardson J.A., Fairbairn A., Blessed G. Nicotinic abnormalities in Alzheimer's disease and Parkinson's disease. J. Neurol. Neurosurg. Pschiatr. 50:1987;806-809.
81. Perry E.K., Smith C.J., Atack J.R., Candy J.M., Johnson M., Perry R.H. Neocortical cholinergic enzyme and receptor activities in the human fetal brain. J. Neurochem. 47:1986;1262-1269.
82. Perry E.K., Smith C.J., Court J.A., Perry R.H. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J. Neural Transm. (PD sect.). 2:1990;149-158.
83. Picciotto M.R., Zoli M., Lèna C., Bessis A., Lallemand Y., LeNovère N., Vincent P., Merlo Pich E., Brûlet P., Changeux J.-P. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature. 374:1995;65-67.
84. Pinkas-Kramarski R., Stein R., Lindenboim L., Sokolovsky M. Growth factor-like effects mediated by muscarinic receptors in PC12M1 cells. J. Neurochem. 59:1992;2158-2166.
85. Poland R., Lutchmansingh P., Au D., Hsieh C., Acosta S., Lydecker S., McCracken J., Afrane S. Exposure to threshold doses of nicotine in utero: II. Neuroendocrine response to nicotine in adult male offspring Dev. Brain Res. 83:1994;278-284.
86. Quirion R., Aubert I., Araujo D.M., Hersi A., Gaudreau P. Autoradiographic distribution of putative muscarinic receptor sub-types in mammalian brain. Prog. Brain Res. 98:1993;85-93.
87. Rakic P., Bourgeois J.-P., Eckenhoff M.F., Zecevic N., Goldman-Rakic P.S. Concurrent overproduction of synapses in diverse regions of the primate cerebral cortex. Science. 232:1986;232-235.
88. 3H-quinuclidinylbenzilate binding sites in frontal cortex. J. Neurochem. 44:1985;240-246.
89. Reddy S., Panigrahy A., White W., Kinney H. Developmental changes in neurotransmitter receptor binding in the human periaqueductal gray. J. Neuropath. Exp. Neurol. 55:1996;409-418.
90. Rinne J.O. Muscarinic and dopaminergic receptors in the aging human brain. Brain Res. 404:1987;162-168.
91. Rooney T., Nahorski S. Postnatal ontogeny of agonist and depolarization-induced phosphoinositide hydrolysis in rat cerebral cortex. J. Pharmacol. Exp. Ther. 243:1987;333-341.
92. Roy T., Sabherwal U. Effects of prenatal nicotine exposure on the morphogenesis of the somatosensory cortex. Neurotox. Terat. 16:1994;411-421.
93. Saito S., Komiya Y., Igarashi M. Muscarinic acetylcholine receptors are expressed and enriched in growth cone membranes isolated from fetal and neonatal forebrain: pharmacological demonstration and characterization. Neuroscience. 45:1991;735-745.
94. Schröder H., Giacobini E., Struble R.G., Zilles K., Maelicke A. Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol. Aging. 12:1991;259-262.
95. Sershen H., Reith M., Banay-Schwartz M., Lajtha A. Effects of prenatal administration of nicotine on amino acid pools, protein metabolism, and nicotine binding in the brain. Neurochem. Res. 7:1982;1515-1522.
96. Sherman K., Friedman E. Pre- and post-synaptic cholinergic dysfunction in aged rodent brain regions: New findings and an interpretative review. Int. J. Dev. Neurosci. 8:1990;689-708.
97. Sirvio J., Hervonen A., Riekkinen P. Cholinergic binding in the hippocampus of the aging male rat. Comp. Biochem. Physiol. 90:1988;C161-C163.
98. Slotkin T., Cho H., Whitmore W. Effects of prenatal nicotine exposure on neuronal development: selective actions on central and peripheral catecholaminergic pathways. Brain Res. Bull. 18:1987;601-611.
99. Slotkin T., Greer N., Faust J., Cho H., Seidler J. Effects of maternal nicotine injections on brain development in the rat: ornithine decarboxylase activity, nucleic acids and proteins in discrete brain regions. Brain Res. Bull. 17:1986;41-50.
100. Slotkin T., Orband-Miller L., Queen K., Whitmore W., Seidler F. Effects of pre-natal nicotine exposure on biochemical development of rat brain regions: maternal drug infusions via osmotic minipumps. J. Pharmacol. Exp. Ther. 240:1987;602-611.
101. Slotkin T.A., Lappi S.E., Seidler F.J. Impact of fetal nicotine exposure on development of rat brain regions: critical sensitive periods or effects withdrawal? Brain Res. Bull. 31:1993;319-328.
102. Slotkin T.A., McCook E.C., Lappi S.E., Seidler F.J. Altered development of basal and forskolin-stimulated adenylate cyclase activity in brain regions of rats exposed to nicotine prenatally. Dev. Brain Res. 68:1992;233-239.
103. Smith W., Seidler F., Slotkin T. Acute stimulation of ornithine decarboxylase in neonatal rat brain regions by nicotine: A central receptor-mediated process. Dev. Brain Res. 63:1991;85-93.
104. Sugaya K., Giacobini E., Chiappinelli V.A. Nicotinic acetylcholine receptor subtypes in human frontal cortex: changes in Alzheimer's disease. J. Neurosci. Res. 27:1990;349-359.
105. 3H]Nicotine binding sites in developing fetal brains in rats. Neurosci. Res. 2:1985;387-392.
106. Surichamorn W., Abdallah E.A.M., El-Fakahany E.E. Aging does not alter brain muscarinic receptor-mediated phosphoinositide hydrolysis and its inhibition by phorbol esters, tetrodotoxin and receptor desensitization. J. Pharmacol. Exp. Ther. 251:1989;543-549.
107. Tan X.T., Costa L.G. Postnatal development of muscarinic receptor-stimulated phosphoinositide metabolism in mouse cerebral cortex: sensitivity to ethanol. Dev. Brain Res. 86:1995;348-353.
108. Tandon P., Mundy W., Ali S., Nanry K., Rogers B., Tilson H. Age-dependent changes in receptor-stimulated phosphoinositide turnover in the rat hippocampus. Pharmacol. Biochem. Behav. 38:1991;861-867.
109. Tollefson G.D., Gade J. A comparison of human muscarinic cholinergic receptor properties subsequent to alcohol abuse and senescence. Biol. Psychiatry. 18:1983;481-491.
110. Undie A.S., Wang H.Y., Friedman E. Decreased phopholipase C-beta immunoreactivity, phosphoinositide metabolism, and protein kinase C activation in senescent F-344 rat brain. Neurobiol. Aging. 16:1995;19-28.
111. van de Kamp J.L., Collins A.C. Prenatal nicotine alters nicotinic receptor development in the mouse brain. Pharmacol. Biochem. Behav. 47:1994;889-900.
112. van Huizen F., March D., Cynander M.S., Shaw C. Muscarinic receptor characteristics and regulation in rat cerebral coertex: changes during development, aging and the oestrous cycle. Eur. J. Neurosci. 6:1994;237-243.
113. Vilarò M.T., Mengod G., Palacios J.M. Advances and limitations of the molecular neuroanatomy of cholinergic receptors: The example of multiple muscarinic receptors. Prog. Brain Res. 98:1993;95-101.
114. 4) in rat forebrain. Mol. Pharmacol. 38:1990;267-273.
115. Waller S., London E. Age-differences in choline acetyltransferase activities and muscarinic receptor binding in brain regions of C57BL/6J mice. Exp. Geront. 18:1983;419-425.
116. Whitney K., Seidler F., Slotkin T. Developmental neurotoxicity of chlorpyrifos: cellular mechanisms. Toxicol. Appl. Pharm. 134:1995;53-62.
117. Whyte J., Harrison R., Lunt G.G., Wonnacott S. Properties of α-bungarotoxin binding sites in foetal human brain. Neurochem. Int. 7:1985;515-523.
118. Wyper D.J., Brown D., Patterson J., Owens J., Hunter R., Teasdale E., McCulloch J. Deficits in iodine-labelled 3-quinuclidinyl benzilate binding in relation to cerebral blood flow in patients with Alzheimer's disease. Eur. J. Nucl. Med. 20:1993;379-386.
119. Yamada S., Kagawa Y., Isogai M., Takayanagi N., Hayashi E. Ontogenesis of nicotinic acetylcholine receptors and presynaptic cholinergic neurons in mammalian brain. Life Sci. 38:1986;637-644.
120. Yanai J., Pick C., Rogel-Fuchs Y., Zahalka E. Alterations in hippocampal cholinergic receptors and hippocampal behaviors after early exposure to nicotine. Brain Res. Bull. 29:1992;363-368.
121. 3H]hemicholinium-3 binding. Neurotox. Terat. 14:1992;375-382.
122. Zhang X., Wahlström G., Nordberg A. Influence of development and aging on nicotinic receptor subtypes in rodent brain. Int. J. Dev. Neurosci. 8:1990;715-721.
123. Zheng J.Q., Felder M., Connor J.A., Poo M.-M. Turning of nerve growth cones induced by neurotransmitters. Nature. 368:1994;140-144.
124. Zhu J., Takita M., Konishi Y., Sudo M., Muramatsu I. Chronic nicotine treatment delays the developmental increase in brain muscarinic receptors in rat neonate. Brain Res. 732:1996;257-260.